Alder Biopharmaceuticals Inc (NASDAQ:ALDR) Given Average Rating of “Buy” by Brokerages

Shares of Alder Biopharmaceuticals Inc (NASDAQ:ALDR) have been given a consensus recommendation of “Buy” by the fifteen analysts that are covering the stock, MarketBeat Ratings reports. Two research analysts have rated the stock with a sell recommendation, three have assigned a hold recommendation and ten have given a buy recommendation to the company. The average 12-month price objective among brokers that have issued ratings on the stock in the last year is $20.10.

ALDR has been the topic of several recent research reports. BidaskClub lowered shares of Vertex Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Tuesday, July 9th. Credit Suisse Group initiated coverage on shares of LTC Properties in a report on Wednesday, July 10th. They issued an “underperform” rating and a $19.00 price target on the stock. Cantor Fitzgerald reaffirmed a “buy” rating and issued a $25.00 price target on shares of Menlo Therapeutics in a report on Thursday, May 2nd. Svb Leerink started coverage on shares of Alder Biopharmaceuticals in a report on Tuesday, May 28th. They issued an “outperform” rating on the stock. Finally, Mizuho set a $100.00 target price on shares of PRA Health Sciences and gave the stock a “hold” rating in a research note on Friday, May 3rd.

In other news, EVP James B. Bucher sold 1,897 shares of the stock in a transaction dated Thursday, April 25th. The shares were sold at an average price of $13.85, for a total transaction of $26,273.45. Following the sale, the executive vice president now directly owns 11,706 shares of the company’s stock, valued at approximately $162,128.10. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. Corporate insiders own 15.40% of the company’s stock.

Several hedge funds have recently bought and sold shares of ALDR. Samlyn Capital LLC raised its position in shares of Alder Biopharmaceuticals by 47.2% during the 4th quarter. Samlyn Capital LLC now owns 2,818,788 shares of the biopharmaceutical company’s stock worth $28,892,000 after purchasing an additional 904,098 shares during the last quarter. Dimensional Fund Advisors LP raised its position in shares of Alder Biopharmaceuticals by 22.7% during the 4th quarter. Dimensional Fund Advisors LP now owns 1,162,005 shares of the biopharmaceutical company’s stock worth $11,910,000 after purchasing an additional 215,098 shares during the last quarter. Geode Capital Management LLC raised its position in shares of Alder Biopharmaceuticals by 4.7% during the 4th quarter. Geode Capital Management LLC now owns 648,440 shares of the biopharmaceutical company’s stock worth $6,646,000 after purchasing an additional 29,296 shares during the last quarter. Millennium Management LLC raised its position in shares of Alder Biopharmaceuticals by 168.5% during the 4th quarter. Millennium Management LLC now owns 477,310 shares of the biopharmaceutical company’s stock worth $4,892,000 after purchasing an additional 299,538 shares during the last quarter. Finally, Fosun International Ltd raised its position in shares of Alder Biopharmaceuticals by 26.5% during the 1st quarter. Fosun International Ltd now owns 233,858 shares of the biopharmaceutical company’s stock worth $3,113,000 after purchasing an additional 49,045 shares during the last quarter.

NASDAQ:ALDR traded down $0.93 during mid-day trading on Tuesday, hitting $10.45. The company’s stock had a trading volume of 1,456,467 shares, compared to its average volume of 1,031,633. Alder Biopharmaceuticals has a 1 year low of $9.44 and a 1 year high of $20.87. The company has a current ratio of 8.34, a quick ratio of 8.34 and a debt-to-equity ratio of 1.21. The company has a market capitalization of $946.06 million, a PE ratio of -2.15 and a beta of 2.56. The business’s fifty day moving average price is $11.48.

Alder Biopharmaceuticals (NASDAQ:ALDR) last posted its quarterly earnings results on Thursday, May 2nd. The biopharmaceutical company reported ($1.63) EPS for the quarter, missing the consensus estimate of ($1.16) by ($0.47). On average, equities research analysts predict that Alder Biopharmaceuticals will post -4.43 EPS for the current fiscal year.

About Alder Biopharmaceuticals

Alder BioPharmaceuticals, Inc operates as a clinical-stage biopharmaceutical company. It discovers, develops, and commercializes therapeutic antibodies to transform the treatment paradigm for patients with migraine in the United States, Australia, and Ireland. The company's lead product candidate is eptinezumab, a monoclonal antibody (mAb) inhibiting calcitonin gene-related peptide, which is in the late-stage clinical development for the prevention of migraine.

Featured Story: Book Value Per Share – BVPS

Analyst Recommendations for Alder Biopharmaceuticals (NASDAQ:ALDR)

Receive News & Ratings for Alder Biopharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alder Biopharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.